Amarantus Bioscience Holdings Inc (AMBS)

[Joefyffe]

Another 8-K...More news just released.

Item 8.01. Other Events

On November 27, 2012 Amarantus BioSciences, Inc. released the results of an Independent Academic Study report demonstrating that MANF (mesencephalic astrocyte-derived neurotrophic factor), the Company’s leading drug candidate for treatment for Parkinson’s disease, when administered in the striatum in the ventral midbrain, diffused exceptionally well. The accepted cause of Parkinson’s disease is the death of 70-80% of the dopaminergic (DAergic) neurons in the SNc in the ventral midbrain, which leads to lack of innervation in the striatum. Previous animal model studies directed to Parkinson’s disease have shown that the inability of neurotrophic factors to properly diffuse from the site of delivery has been a key technological impediment to developing new treatments for Parkinson’s disease.

The Independent Study indicates that MANF, the Company’s leading drug candidate, diffuses from the point of delivery in the brain more favorably than GDNF; thus, providing a firm basis for the continue investment in MANF development. The next step in MANF development is clinical studies utilizing a primate model. If those studies are positive, they will be incorporated in the toxicological data of an investigational new drug application package to the FDA to be submitted prior to starting a Phase I/II clinical trial for MANF in the treatment of Parkinson’s disease.

http://ih.advfn.com/p.php?pid=nmona&article=55198065